CTIS2023-507425-42-00进行中（未招募）1 期
A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - VanC-IT
niversity Of Milano Bicocca0 个研究点目标入组 84 人开始时间: 2023年10月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •1. Willing and able to give informed consent prior to any study specific procedure being performed; 2. Male and non-pregnant, non-lactating female subjects, including women of child bearing potential (WOCBP), between 15-70 years of age at the time of informed consent; 3. Diagnosis of large-duct PSC based on cholangiogram (at MRCP, Endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiography [PTC]) according to the most recent published guidelines (EASL); 4. Baseline ALP =1.5 times upper limit normal at screening; 5. Absence of biliary obstruction and/or malignancy within 6-12 months of entry into the study; 6. If a patient is on ursodeoxycholic acid (UDCA) or 5-aminosalicylic acid he or she is expected to remain on the same daily dose during the study period; 7. Patients who received antibiotics or probiotics may participate if they had a washout period of at least 3-month prior to study entry; 8. If a patient has been on obeticholic acid or other experimental therapies (e.g. cilofexor and norUDCA) for PSC, they must complete a 3-month washout period before study entry; 9. PSC with or without IBD. IBD diagnosis should be documented and with a minimum disease duration of 6 months, as determined by endoscopic and histopathology assessment. IBD should be in clinical remission or mildly active according to CDAI and partial Mayo score for CD and UC, respectively (i.e. patients with CDAI score < 220 and pMayo score <5). Patients without documented IBD need a colonoscopy with segmental biopsies within 12 months prior to baseline visit; 10. Female subjects of childbearing potential must test negative for pregnancy at screening, baseline and follow-up visits and if engage in sexual intercourse must agree to use specific methods of contraception.
排除标准
- •1. Receiving an antibiotic or probiotic within 3 months prior to the study; 2. Expected to receive antibiotics within the weeks leading up to enrollment (such as patients with recurrent cholangitis, ongoing infectious illnesses, etc.) ; 3. Allergy to vancomycin or teicoplanin; 4. Biliary intervention within 3 months prior to study enrollment or planned; 5. Alcohol abuse (defined as greater than 14 standard drinks units per week in men; greater than 7 standard drinks units per week); 6. Pregnancy and lactation; 7. Advanced renal disease (glomerular filtration rate [GFR ]< 70); 8. Active hepatitis B and/or C infection; 9. Other chronic or cholestatic liver diseases such as primary biliary cholangitis (PBC), autoimmune hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, Wilson’s disease, hemochromatosis, a-1 antitrypsin deficiency, IgG4-related sclerosing cholangitis, and liver cancer; 10. History of cholangiocarcinoma [CCA]; 11. Advanced liver disease (history of variceal bleeding, ascites, hepatic encephalopathy, and/or bilirubine >4 mg/dL) ; 12. On active transplantation list; 13. IBD with uncontrolled moderate to severe activity; 14. Treatment with any immunosuppressive medication for controlling IBD (i.e. azathioprine, 6-mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with corticosteroids (including budesonide, budesonide MMX and beclomethasone) in the previous four weeks; 15. Treatment with rifampicin; 16. Dose change within last 3 months prior to baseline of concomitant treatment with vitamin D or fibrates; 17. Treatment with any experimental drug within the previous three months; 18. Any known relevant infectious disease (e.g. active tuberculosis, AIDS defining disease); 19. Any active malignant disease; 20. Well found doubt about patient’s cooperation, e.g. addiction to alcohol or drugs; 21. Imprisoned person, person admitted to nursing homes, persons under legal guardianship, and persons not able to express their consent.
研究者
相似试验
暂停
不适用
To study the effect of Tofacitinib along with corticosteroids in patients with acute severe ulcerative colitis.CTRI/2022/08/044613Dr Ajit Sood
撤回
不适用
A Prospective, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Performance of the IBV Valve System for the Treatment of Severe Emphysemasevere emphysema10006436NL-OMON30950Spiration Inc.10
撤回
不适用
A Prospective, randomized , placebo, controlled trial ( double blinded) to assess the potential role of vitamin D treatment in breast cancer patientsbreast cancer/ breast carcinoma10006291NL-OMON34378Medisch Spectrum Twente110
已完成
不适用
A prospective, randomised, placebo-controlled, blinded trial of gabapentin in chronic groin pain following groin hernia repairSigns and Symptoms: PainSigns and SymptomsPainISRCTN43433116Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
招募中
3 期
Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy2024-514090-21-00Inmunotek S.L.150